Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension

Starting soon

Conditions studied: Pulmonary Arterial Hypertension (PAH)

In brief

Pulmonary arterial hypertension (PAH) is a rare and serious condition that affects the blood vessels of the lungs and can significantly limit daily activities and quality of life. Some patients with PAH use inhaled iloprost, a medication that requires several inhalations per day, which can be difficult to maintain over time. Oral selexipag is an alternative treatment that may reduce treatment burden and improve adherence. The PROMISE study aims to evaluate how switching from inhaled iloprost to oral selexipag affects patients' quality of life, satisfaction with treatment, and adherence in real-world clinical practice. Patient-reported outcome questionnaires will be used to understand patients' perceptions of symptoms, daily functioning, and overall improvement after the transition. Adult patients with PAH who are receiving inhaled iloprost and whose physicians decide to switch treatment to oral selexipag will be followed over time. A comparison group of patients who continue using inhaled iloprost will also be observed. The study does not involve any experimental treatment or changes to routine clinical care. All medications are prescribed as part of standard medical practice. The results of this study may help improve understanding of the patient experience during treatment transitions in PAH and support more patient-centered treatment decisions.

Key facts

Study ID

NCT07356375

Run by

University of Sao Paulo General Hospital

People needed

32

Starts

2026-03-01

Expected to finish

2026-12-31

Last updated by the study team

2026-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 years or older.
• Confirmed diagnosis of pulmonary arterial hypertension (PAH, Group 1) by right heart catheterization.
• Current treatment with inhaled iloprost as part of routine clinical care.
• Clinical decision by the treating physician to transition from inhaled iloprost to oral selexipag.
• Ability to understand and complete patient-reported outcome questionnaires.
• Provision of written informed consent.

You may not qualify if…

• Significant cognitive impairment or sensory deficits that prevent completion of study questionnaires.
• Unstable or decompensated comorbid conditions that may interfere with treatment adherence or study participation.
• Refusal or inability to provide informed consent.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.